Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
pharmaceutical investing Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
pharmaceutical investing Antibe Provides Scientific Report on Its Recently Completed Phase 2B Study Showing Unequivocal Gastrointestinal Safety of ATB-346
Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346
pharmaceutical investing Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
SAGA Metals Completes Phase 2 of Major Drill Program at the Radar Project in Labrador-Confirms Extensive Oxide Mineralization in All Drill Locations at Trapper North and South Zones & Provides Corporate Update
ReeXploration Announces Field Program Results Confirming Large-Scale Uranium Target at Eureka, Namibia
